nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Mometasone—systemic scleroderma	0.13	0.287	CbGbCtD
Irbesartan—CYP1A2—Pentoxifylline—systemic scleroderma	0.0682	0.15	CbGbCtD
Irbesartan—CYP1A2—Leflunomide—systemic scleroderma	0.065	0.143	CbGbCtD
Irbesartan—CYP2C9—Leflunomide—systemic scleroderma	0.0586	0.129	CbGbCtD
Irbesartan—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0519	0.114	CbGbCtD
Irbesartan—CYP2D6—Captopril—systemic scleroderma	0.042	0.0926	CbGbCtD
Irbesartan—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.021	0.0464	CbGbCtD
Irbesartan—CYP2C9—cardial valve—systemic scleroderma	0.0182	0.187	CbGeAlD
Irbesartan—CYP3A4—Prednisone—systemic scleroderma	0.0168	0.0371	CbGbCtD
Irbesartan—JUN—artery—systemic scleroderma	0.00754	0.0772	CbGeAlD
Irbesartan—JUN—endothelium—systemic scleroderma	0.00637	0.0652	CbGeAlD
Irbesartan—JUN—blood vessel—systemic scleroderma	0.00587	0.0601	CbGeAlD
Irbesartan—AGTR1—artery—systemic scleroderma	0.00567	0.0581	CbGeAlD
Irbesartan—AGTR1—endothelium—systemic scleroderma	0.00479	0.0491	CbGeAlD
Irbesartan—EDNRA—EGFR-dependent Endothelin signaling events—EDN1—systemic scleroderma	0.0047	0.0441	CbGpPWpGaD
Irbesartan—AGTR1—blood vessel—systemic scleroderma	0.00442	0.0453	CbGeAlD
Irbesartan—JUN—Integrin-linked kinase signaling—GIT2—systemic scleroderma	0.00411	0.0386	CbGpPWpGaD
Irbesartan—UGT1A3—digestive system—systemic scleroderma	0.00384	0.0393	CbGeAlD
Irbesartan—JUN—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.00322	0.0302	CbGpPWpGaD
Irbesartan—JUN—connective tissue—systemic scleroderma	0.00301	0.0308	CbGeAlD
Irbesartan—AGTR1—ACE Inhibitor Pathway—ACE—systemic scleroderma	0.0029	0.0272	CbGpPWpGaD
Irbesartan—JUN—smooth muscle tissue—systemic scleroderma	0.00275	0.0282	CbGeAlD
Irbesartan—JUN—skin of body—systemic scleroderma	0.00272	0.0278	CbGeAlD
Irbesartan—PTGS1—artery—systemic scleroderma	0.00249	0.0256	CbGeAlD
Irbesartan—EDNRA—tendon—systemic scleroderma	0.00227	0.0232	CbGeAlD
Irbesartan—AGTR1—connective tissue—systemic scleroderma	0.00227	0.0232	CbGeAlD
Irbesartan—JUN—digestive system—systemic scleroderma	0.00217	0.0223	CbGeAlD
Irbesartan—PTGS1—endothelium—systemic scleroderma	0.00211	0.0216	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—systemic scleroderma	0.00207	0.0212	CbGeAlD
Irbesartan—JUN—tendon—systemic scleroderma	0.00207	0.0212	CbGeAlD
Irbesartan—EDNRA—lung—systemic scleroderma	0.00199	0.0204	CbGeAlD
Irbesartan—PTGS1—blood vessel—systemic scleroderma	0.00194	0.0199	CbGeAlD
Irbesartan—EDNRA—Endothelins—COL1A2—systemic scleroderma	0.00183	0.0172	CbGpPWpGaD
Irbesartan—JUN—lung—systemic scleroderma	0.00182	0.0186	CbGeAlD
Irbesartan—EDNRA—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.00179	0.0168	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—CD247—systemic scleroderma	0.00176	0.0165	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.00166	0.0156	CbGpPWpGaD
Irbesartan—EDNRA—Endothelin Pathways—EDN1—systemic scleroderma	0.00166	0.0156	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IL13—systemic scleroderma	0.00166	0.0156	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—COL1A2—systemic scleroderma	0.00164	0.0154	CbGpPWpGaD
Irbesartan—JUN—Betamethasone—Mometasone—systemic scleroderma	0.00163	0.324	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Mometasone—systemic scleroderma	0.00163	0.324	CbGdCrCtD
Irbesartan—AGTR1—tendon—systemic scleroderma	0.00156	0.016	CbGeAlD
Irbesartan—JUN—IL12 signaling mediated by STAT4—STAT4—systemic scleroderma	0.00155	0.0146	CbGpPWpGaD
Irbesartan—JUN—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.00146	0.0137	CbGpPWpGaD
Irbesartan—JUN—CD40/CD40L signaling—TNFAIP3—systemic scleroderma	0.00143	0.0134	CbGpPWpGaD
Irbesartan—AGTR1—lung—systemic scleroderma	0.00137	0.014	CbGeAlD
Irbesartan—AGTR1—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.00135	0.0127	CbGpPWpGaD
Irbesartan—JUN—Physiological and Pathological Hypertrophy  of the Heart—EDN1—systemic scleroderma	0.00122	0.0114	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.0012	0.0113	CbGpPWpGaD
Irbesartan—JUN—Endothelins—COL1A2—systemic scleroderma	0.00107	0.0101	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00107	0.01	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL13—systemic scleroderma	0.00102	0.00961	CbGpPWpGaD
Irbesartan—EDNRA—Endothelin Pathways—NOS3—systemic scleroderma	0.00101	0.0095	CbGpPWpGaD
Irbesartan—PTGS1—connective tissue—systemic scleroderma	0.000996	0.0102	CbGeAlD
Irbesartan—EDNRA—Endothelins—EDN1—systemic scleroderma	0.00099	0.00929	CbGpPWpGaD
Irbesartan—JUN—BCR signaling pathway—CSK—systemic scleroderma	0.000985	0.00925	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000985	0.00925	CbGpPWpGaD
Irbesartan—JUN—IL1-mediated signaling events—IL1A—systemic scleroderma	0.000945	0.00887	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000938	0.0088	CbGpPWpGaD
Irbesartan—PTGS1—smooth muscle tissue—systemic scleroderma	0.000912	0.00934	CbGeAlD
Irbesartan—PTGS1—skin of body—systemic scleroderma	0.0009	0.00922	CbGeAlD
Irbesartan—JUN—CD40/CD40L signaling—CD40LG—systemic scleroderma	0.000898	0.00842	CbGpPWpGaD
Irbesartan—AGTR1—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.000892	0.00838	CbGpPWpGaD
Irbesartan—JUN—Dexamethasone—Prednisone—systemic scleroderma	0.000888	0.176	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—systemic scleroderma	0.000888	0.176	CbGdCrCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000887	0.00833	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000877	0.00823	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—GDF15—systemic scleroderma	0.00087	0.00817	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.000862	0.00809	CbGpPWpGaD
Irbesartan—Losartan—ACE—systemic scleroderma	0.00086	1	CrCbGaD
Irbesartan—EDNRA—Endothelins—MMP1—systemic scleroderma	0.000832	0.00781	CbGpPWpGaD
Irbesartan—CYP1A2—digestive system—systemic scleroderma	0.000831	0.00851	CbGeAlD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.000826	0.00775	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—CTLA4—systemic scleroderma	0.000824	0.00773	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.000813	0.00763	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—IRF5—systemic scleroderma	0.000809	0.00759	CbGpPWpGaD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—IL1A—systemic scleroderma	0.000798	0.00749	CbGpPWpGaD
Irbesartan—CYP2C9—digestive system—systemic scleroderma	0.000788	0.00807	CbGeAlD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP1—systemic scleroderma	0.000747	0.00701	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000743	0.00697	CbGpPWpGaD
Irbesartan—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.000733	0.00688	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD247—systemic scleroderma	0.000732	0.00687	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.00073	0.00685	CbGpPWpGaD
Irbesartan—PTGS1—digestive system—systemic scleroderma	0.00072	0.00737	CbGeAlD
Irbesartan—CYP1A2—lung—systemic scleroderma	0.000694	0.0071	CbGeAlD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.000693	0.0065	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00069	0.00648	CbGpPWpGaD
Irbesartan—PTGS1—tendon—systemic scleroderma	0.000685	0.00701	CbGeAlD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000679	0.00637	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000678	0.00637	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000677	0.00635	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000673	0.00632	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—BLK—systemic scleroderma	0.000671	0.0063	CbGpPWpGaD
Irbesartan—JUN—Osteopontin-mediated events—MMP2—systemic scleroderma	0.000666	0.00625	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TOP1—systemic scleroderma	0.000652	0.00612	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL1A—systemic scleroderma	0.000644	0.00605	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—IL1A—systemic scleroderma	0.000643	0.00604	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—CD40LG—systemic scleroderma	0.000641	0.00601	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000638	0.00598	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000608	0.0057	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—systemic scleroderma	0.000607	0.0057	CbGpPWpGaD
Irbesartan—CYP3A4—digestive system—systemic scleroderma	0.000601	0.00616	CbGeAlD
Irbesartan—PTGS1—lung—systemic scleroderma	0.000601	0.00616	CbGeAlD
Irbesartan—JUN—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000598	0.00562	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.000593	0.00557	CbGpPWpGaD
Irbesartan—CYP2D6—digestive system—systemic scleroderma	0.000592	0.00606	CbGeAlD
Irbesartan—JUN—Endothelins—EDN1—systemic scleroderma	0.00058	0.00545	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—systemic scleroderma	0.000578	0.00542	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000574	0.00538	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000569	0.00534	CbGpPWpGaD
Irbesartan—JUN—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000559	0.00525	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000549	0.00515	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—NOS3—systemic scleroderma	0.000541	0.00508	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000541	0.00508	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—IRF5—systemic scleroderma	0.000538	0.00505	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000533	0.00501	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000521	0.00489	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000511	0.0048	CbGpPWpGaD
Irbesartan—JUN—Osteopontin-mediated events—MMP9—systemic scleroderma	0.0005	0.0047	CbGpPWpGaD
Irbesartan—JUN—IL1-mediated signaling events—IL1B—systemic scleroderma	0.000493	0.00463	CbGpPWpGaD
Irbesartan—JUN—Endothelins—MMP1—systemic scleroderma	0.000488	0.00458	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000486	0.00456	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000484	0.00454	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.00048	0.0045	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—RHOB—systemic scleroderma	0.00047	0.00441	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—MMP1—systemic scleroderma	0.000448	0.00421	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000444	0.00417	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—COL1A2—systemic scleroderma	0.000443	0.00416	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000442	0.00415	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—systemic scleroderma	0.000434	0.00408	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000434	0.00407	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—TGFB1—systemic scleroderma	0.000423	0.00397	CbGpPWpGaD
Irbesartan—EDNRA—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000415	0.00389	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000409	0.00384	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—ITGAM—systemic scleroderma	0.000402	0.00378	CbGpPWpGaD
Irbesartan—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.0004	0.00375	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000398	0.00373	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000395	0.00371	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000392	0.00368	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000387	0.00363	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL1A—systemic scleroderma	0.000383	0.0036	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000383	0.0036	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—MMP2—systemic scleroderma	0.000373	0.0035	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000373	0.0035	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—BLK—systemic scleroderma	0.000372	0.0035	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000371	0.00348	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—CCL2—systemic scleroderma	0.000365	0.00342	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000364	0.00341	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000341	0.0032	CbGpPWpGaD
Irbesartan—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000339	0.00318	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL1B—systemic scleroderma	0.000336	0.00315	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000335	0.00315	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—EDN1—systemic scleroderma	0.000325	0.00305	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.000321	0.00301	CbGpPWpGaD
Irbesartan—JUN—FGF signaling pathway—MMP9—systemic scleroderma	0.000321	0.00301	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000312	0.00293	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000301	0.00282	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000293	0.00275	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000291	0.00273	CbGpPWpGaD
Irbesartan—JUN—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000286	0.00268	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—MMP9—systemic scleroderma	0.00028	0.00263	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00028	0.00263	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000279	0.00262	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000275	0.00258	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000273	0.00257	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.00027	0.00253	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000264	0.00248	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000263	0.00247	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TGFB1—systemic scleroderma	0.000261	0.00245	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—MMP9—systemic scleroderma	0.000261	0.00245	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL1A—systemic scleroderma	0.000243	0.00228	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000242	0.00227	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000234	0.0022	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—RHOB—systemic scleroderma	0.000231	0.00217	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000226	0.00212	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—TGFB1—systemic scleroderma	0.00022	0.00206	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00022	0.00206	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000215	0.00202	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TGFB1—systemic scleroderma	0.000215	0.00202	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.000212	0.00199	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—RHOB—systemic scleroderma	0.00021	0.00197	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—EDN1—systemic scleroderma	0.000209	0.00196	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000205	0.00192	CbGpPWpGaD
Irbesartan—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000202	0.0006	CcSEcCtD
Irbesartan—Feeling abnormal—Leflunomide—systemic scleroderma	0.000201	0.000599	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000201	0.000599	CcSEcCtD
Irbesartan—Fatigue—Mycophenolic acid—systemic scleroderma	0.000201	0.000598	CcSEcCtD
Irbesartan—Mood swings—Methotrexate—systemic scleroderma	0.000201	0.000598	CcSEcCtD
Irbesartan—Nausea—Mometasone—systemic scleroderma	0.0002	0.000597	CcSEcCtD
Irbesartan—Anorexia—Lisinopril—systemic scleroderma	0.0002	0.000596	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.0002	0.00188	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.0002	0.000595	CcSEcCtD
Irbesartan—Weight increased—Prednisone—systemic scleroderma	0.0002	0.000594	CcSEcCtD
Irbesartan—Pain—Mycophenolic acid—systemic scleroderma	0.000199	0.000593	CcSEcCtD
Irbesartan—Constipation—Mycophenolic acid—systemic scleroderma	0.000199	0.000593	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—MMP2—systemic scleroderma	0.000199	0.00187	CbGpPWpGaD
Irbesartan—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000198	0.00059	CcSEcCtD
Irbesartan—Hyperglycaemia—Prednisone—systemic scleroderma	0.000198	0.000589	CcSEcCtD
Irbesartan—Cough—Mycophenolate mofetil—systemic scleroderma	0.000197	0.000585	CcSEcCtD
Irbesartan—Hypotension—Lisinopril—systemic scleroderma	0.000196	0.000584	CcSEcCtD
Irbesartan—Dizziness—Captopril—systemic scleroderma	0.000196	0.000583	CcSEcCtD
Irbesartan—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000196	0.000583	CcSEcCtD
Irbesartan—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000579	CcSEcCtD
Irbesartan—Urticaria—Leflunomide—systemic scleroderma	0.000194	0.000578	CcSEcCtD
Irbesartan—Body temperature increased—Leflunomide—systemic scleroderma	0.000193	0.000575	CcSEcCtD
Irbesartan—Abdominal pain—Leflunomide—systemic scleroderma	0.000193	0.000575	CcSEcCtD
Irbesartan—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000193	0.000574	CcSEcCtD
Irbesartan—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000192	0.000572	CcSEcCtD
Irbesartan—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000571	CcSEcCtD
Irbesartan—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000571	CcSEcCtD
Irbesartan—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000571	CcSEcCtD
Irbesartan—Myocardial infarction—Prednisone—systemic scleroderma	0.000192	0.00057	CcSEcCtD
Irbesartan—Breast disorder—Methotrexate—systemic scleroderma	0.000192	0.00057	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000191	0.000569	CcSEcCtD
Irbesartan—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000569	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000191	0.000568	CcSEcCtD
Irbesartan—Hypersensitivity—Azathioprine—systemic scleroderma	0.000191	0.000567	CcSEcCtD
Irbesartan—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000191	0.000567	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000567	CcSEcCtD
Irbesartan—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000564	CcSEcCtD
Irbesartan—Paraesthesia—Lisinopril—systemic scleroderma	0.000188	0.000561	CcSEcCtD
Irbesartan—Vomiting—Captopril—systemic scleroderma	0.000188	0.000561	CcSEcCtD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000188	0.00176	CbGpPWpGaD
Irbesartan—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000188	0.000559	CcSEcCtD
Irbesartan—Dyspnoea—Lisinopril—systemic scleroderma	0.000187	0.000557	CcSEcCtD
Irbesartan—Rash—Captopril—systemic scleroderma	0.000187	0.000556	CcSEcCtD
Irbesartan—Dermatitis—Captopril—systemic scleroderma	0.000187	0.000556	CcSEcCtD
Irbesartan—Somnolence—Lisinopril—systemic scleroderma	0.000187	0.000555	CcSEcCtD
Irbesartan—Headache—Captopril—systemic scleroderma	0.000186	0.000553	CcSEcCtD
Irbesartan—Dyspepsia—Lisinopril—systemic scleroderma	0.000185	0.00055	CcSEcCtD
Irbesartan—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000184	0.000548	CcSEcCtD
Irbesartan—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000184	0.000548	CcSEcCtD
Irbesartan—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000547	CcSEcCtD
Irbesartan—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000547	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—IL1A—systemic scleroderma	0.000183	0.00172	CbGpPWpGaD
Irbesartan—Asthma—Methotrexate—systemic scleroderma	0.000183	0.000545	CcSEcCtD
Irbesartan—Infection—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000544	CcSEcCtD
Irbesartan—Decreased appetite—Lisinopril—systemic scleroderma	0.000182	0.000543	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000182	0.0017	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000181	0.000539	CcSEcCtD
Irbesartan—Fatigue—Lisinopril—systemic scleroderma	0.000181	0.000539	CcSEcCtD
Irbesartan—Shock—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000539	CcSEcCtD
Irbesartan—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000537	CcSEcCtD
Irbesartan—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000536	CcSEcCtD
Irbesartan—Hypersensitivity—Leflunomide—systemic scleroderma	0.00018	0.000536	CcSEcCtD
Irbesartan—Pancreatitis—Methotrexate—systemic scleroderma	0.00018	0.000535	CcSEcCtD
Irbesartan—Pain—Lisinopril—systemic scleroderma	0.00018	0.000534	CcSEcCtD
Irbesartan—Constipation—Lisinopril—systemic scleroderma	0.00018	0.000534	CcSEcCtD
Irbesartan—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000534	CcSEcCtD
Irbesartan—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000532	CcSEcCtD
Irbesartan—Bradycardia—Prednisone—systemic scleroderma	0.000179	0.000532	CcSEcCtD
Irbesartan—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000529	CcSEcCtD
Irbesartan—Diarrhoea—Azathioprine—systemic scleroderma	0.000177	0.000527	CcSEcCtD
Irbesartan—Nausea—Captopril—systemic scleroderma	0.000176	0.000524	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000176	0.00165	CbGpPWpGaD
Irbesartan—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000522	CcSEcCtD
Irbesartan—Asthenia—Leflunomide—systemic scleroderma	0.000175	0.000522	CcSEcCtD
Irbesartan—Feeling abnormal—Lisinopril—systemic scleroderma	0.000173	0.000515	CcSEcCtD
Irbesartan—Pruritus—Leflunomide—systemic scleroderma	0.000173	0.000514	CcSEcCtD
Irbesartan—Connective tissue disorder—Prednisone—systemic scleroderma	0.000172	0.000513	CcSEcCtD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	0.000172	0.00162	CbGpPWpGaD
Irbesartan—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000172	0.000512	CcSEcCtD
Irbesartan—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000172	0.000511	CcSEcCtD
Irbesartan—Neutropenia—Methotrexate—systemic scleroderma	0.000171	0.00051	CcSEcCtD
Irbesartan—Dizziness—Azathioprine—systemic scleroderma	0.000171	0.000509	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00017	0.000507	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000499	CcSEcCtD
Irbesartan—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000167	0.000498	CcSEcCtD
Irbesartan—Asthenia—Mycophenolic acid—systemic scleroderma	0.000167	0.000498	CcSEcCtD
Irbesartan—Diarrhoea—Leflunomide—systemic scleroderma	0.000167	0.000498	CcSEcCtD
Irbesartan—Urticaria—Lisinopril—systemic scleroderma	0.000167	0.000496	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000166	0.00156	CbGpPWpGaD
Irbesartan—Abdominal pain—Lisinopril—systemic scleroderma	0.000166	0.000494	CcSEcCtD
Irbesartan—Body temperature increased—Lisinopril—systemic scleroderma	0.000166	0.000494	CcSEcCtD
Irbesartan—JUN—Innate Immune System—ITGAM—systemic scleroderma	0.000165	0.00155	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD247—systemic scleroderma	0.000165	0.00155	CbGpPWpGaD
Irbesartan—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000492	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—RHOB—systemic scleroderma	0.000165	0.00155	CbGpPWpGaD
Irbesartan—Pruritus—Mycophenolic acid—systemic scleroderma	0.000165	0.000491	CcSEcCtD
Irbesartan—Vomiting—Azathioprine—systemic scleroderma	0.000164	0.00049	CcSEcCtD
Irbesartan—Pneumonia—Methotrexate—systemic scleroderma	0.000164	0.000489	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—EDN1—systemic scleroderma	0.000164	0.00154	CbGpPWpGaD
Irbesartan—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000488	CcSEcCtD
Irbesartan—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000487	CcSEcCtD
Irbesartan—Rash—Azathioprine—systemic scleroderma	0.000163	0.000485	CcSEcCtD
Irbesartan—Dermatitis—Azathioprine—systemic scleroderma	0.000163	0.000485	CcSEcCtD
Irbesartan—Flushing—Prednisone—systemic scleroderma	0.000163	0.000485	CcSEcCtD
Irbesartan—Headache—Azathioprine—systemic scleroderma	0.000162	0.000482	CcSEcCtD
Irbesartan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000482	CcSEcCtD
Irbesartan—Dizziness—Leflunomide—systemic scleroderma	0.000162	0.000481	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000161	0.00151	CbGpPWpGaD
Irbesartan—Renal failure—Methotrexate—systemic scleroderma	0.000161	0.000478	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—SMAD7—systemic scleroderma	0.00016	0.00151	CbGpPWpGaD
Irbesartan—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000476	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.00016	0.0015	CbGpPWpGaD
Irbesartan—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000159	0.000475	CcSEcCtD
Irbesartan—Angiopathy—Prednisone—systemic scleroderma	0.000159	0.000474	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—systemic scleroderma	0.000159	0.000473	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000473	CcSEcCtD
Irbesartan—Immune system disorder—Prednisone—systemic scleroderma	0.000159	0.000472	CcSEcCtD
Irbesartan—Pain—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000468	CcSEcCtD
Irbesartan—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000468	CcSEcCtD
Irbesartan—Arrhythmia—Prednisone—systemic scleroderma	0.000157	0.000467	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000155	0.00146	CbGpPWpGaD
Irbesartan—Vomiting—Leflunomide—systemic scleroderma	0.000155	0.000462	CcSEcCtD
Irbesartan—JUN—Innate Immune System—TNFAIP3—systemic scleroderma	0.000155	0.00145	CbGpPWpGaD
Irbesartan—Hypersensitivity—Lisinopril—systemic scleroderma	0.000155	0.00046	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000155	0.00046	CcSEcCtD
Irbesartan—Dizziness—Mycophenolic acid—systemic scleroderma	0.000154	0.000459	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—systemic scleroderma	0.000154	0.000459	CcSEcCtD
Irbesartan—Rash—Leflunomide—systemic scleroderma	0.000154	0.000458	CcSEcCtD
Irbesartan—Dermatitis—Leflunomide—systemic scleroderma	0.000154	0.000458	CcSEcCtD
Irbesartan—Nausea—Azathioprine—systemic scleroderma	0.000154	0.000457	CcSEcCtD
Irbesartan—Headache—Leflunomide—systemic scleroderma	0.000153	0.000456	CcSEcCtD
Irbesartan—Erythema—Prednisone—systemic scleroderma	0.000153	0.000455	CcSEcCtD
Irbesartan—Malnutrition—Prednisone—systemic scleroderma	0.000153	0.000455	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—systemic scleroderma	0.000152	0.000454	CcSEcCtD
Irbesartan—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000451	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TGFB1—systemic scleroderma	0.000151	0.00142	CbGpPWpGaD
Irbesartan—Asthenia—Lisinopril—systemic scleroderma	0.000151	0.000448	CcSEcCtD
Irbesartan—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000448	CcSEcCtD
Irbesartan—Pruritus—Lisinopril—systemic scleroderma	0.000149	0.000442	CcSEcCtD
Irbesartan—Vomiting—Mycophenolic acid—systemic scleroderma	0.000148	0.000441	CcSEcCtD
Irbesartan—UGT1A3—NRF2 pathway—TGFB1—systemic scleroderma	0.000148	0.00139	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000147	0.00138	CbGpPWpGaD
Irbesartan—Rash—Mycophenolic acid—systemic scleroderma	0.000147	0.000437	CcSEcCtD
Irbesartan—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000147	0.000437	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—systemic scleroderma	0.000147	0.000437	CcSEcCtD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	0.000146	0.00137	CbGpPWpGaD
Irbesartan—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000435	CcSEcCtD
Irbesartan—Headache—Mycophenolic acid—systemic scleroderma	0.000146	0.000435	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000146	0.00137	CbGpPWpGaD
Irbesartan—Pharyngitis—Methotrexate—systemic scleroderma	0.000146	0.000433	CcSEcCtD
Irbesartan—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000433	CcSEcCtD
Irbesartan—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000433	CcSEcCtD
Irbesartan—Nausea—Leflunomide—systemic scleroderma	0.000145	0.000432	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000145	0.000431	CcSEcCtD
Irbesartan—Vision blurred—Prednisone—systemic scleroderma	0.000144	0.000429	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—systemic scleroderma	0.000144	0.000428	CcSEcCtD
Irbesartan—Diarrhoea—Lisinopril—systemic scleroderma	0.000144	0.000428	CcSEcCtD
Irbesartan—EDNRA—GPCR ligand binding—CCL2—systemic scleroderma	0.000143	0.00134	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Prednisone—systemic scleroderma	0.000142	0.000422	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—systemic scleroderma	0.000141	0.000421	CcSEcCtD
Irbesartan—Anaemia—Prednisone—systemic scleroderma	0.000141	0.00042	CcSEcCtD
Irbesartan—Agitation—Prednisone—systemic scleroderma	0.00014	0.000418	CcSEcCtD
Irbesartan—Angioedema—Prednisone—systemic scleroderma	0.00014	0.000415	CcSEcCtD
Irbesartan—Dizziness—Lisinopril—systemic scleroderma	0.000139	0.000413	CcSEcCtD
Irbesartan—Nausea—Mycophenolic acid—systemic scleroderma	0.000138	0.000412	CcSEcCtD
Irbesartan—Malaise—Prednisone—systemic scleroderma	0.000138	0.00041	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000137	0.00129	CbGpPWpGaD
Irbesartan—Vertigo—Prednisone—systemic scleroderma	0.000137	0.000409	CcSEcCtD
Irbesartan—Syncope—Prednisone—systemic scleroderma	0.000137	0.000408	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—systemic scleroderma	0.000137	0.000407	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—systemic scleroderma	0.000136	0.000405	CcSEcCtD
Irbesartan—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000403	CcSEcCtD
Irbesartan—Loss of consciousness—Prednisone—systemic scleroderma	0.000134	0.0004	CcSEcCtD
Irbesartan—Vomiting—Lisinopril—systemic scleroderma	0.000133	0.000397	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—systemic scleroderma	0.000133	0.000396	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—systemic scleroderma	0.000132	0.000394	CcSEcCtD
Irbesartan—Rash—Lisinopril—systemic scleroderma	0.000132	0.000394	CcSEcCtD
Irbesartan—Dermatitis—Lisinopril—systemic scleroderma	0.000132	0.000394	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000132	0.000393	CcSEcCtD
Irbesartan—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000393	CcSEcCtD
Irbesartan—Hypertension—Prednisone—systemic scleroderma	0.000132	0.000393	CcSEcCtD
Irbesartan—Chills—Methotrexate—systemic scleroderma	0.000132	0.000392	CcSEcCtD
Irbesartan—Headache—Lisinopril—systemic scleroderma	0.000132	0.000391	CcSEcCtD
Irbesartan—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000387	CcSEcCtD
Irbesartan—Arthralgia—Prednisone—systemic scleroderma	0.00013	0.000387	CcSEcCtD
Irbesartan—Myalgia—Prednisone—systemic scleroderma	0.00013	0.000387	CcSEcCtD
Irbesartan—Anxiety—Prednisone—systemic scleroderma	0.00013	0.000386	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.000129	0.00121	CbGpPWpGaD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000129	0.000384	CcSEcCtD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000129	0.00121	CbGpPWpGaD
Irbesartan—Discomfort—Prednisone—systemic scleroderma	0.000128	0.000382	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—systemic scleroderma	0.000128	0.00038	CcSEcCtD
Irbesartan—Erythema—Methotrexate—systemic scleroderma	0.000128	0.00038	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—SMAD7—systemic scleroderma	0.000126	0.00118	CbGpPWpGaD
Irbesartan—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000375	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—systemic scleroderma	0.000125	0.000372	CcSEcCtD
Irbesartan—Nausea—Lisinopril—systemic scleroderma	0.000125	0.000371	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—systemic scleroderma	0.000125	0.000371	CcSEcCtD
Irbesartan—Oedema—Prednisone—systemic scleroderma	0.000125	0.000371	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—RHOB—systemic scleroderma	0.000124	0.00117	CbGpPWpGaD
Irbesartan—Infection—Prednisone—systemic scleroderma	0.000124	0.000369	CcSEcCtD
Irbesartan—Shock—Prednisone—systemic scleroderma	0.000123	0.000365	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—systemic scleroderma	0.000122	0.000364	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—systemic scleroderma	0.000122	0.000362	CcSEcCtD
Irbesartan—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000362	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000121	0.00114	CbGpPWpGaD
Irbesartan—Skin disorder—Prednisone—systemic scleroderma	0.000121	0.00036	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—systemic scleroderma	0.000121	0.000359	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—systemic scleroderma	0.00012	0.000358	CcSEcCtD
Irbesartan—Anorexia—Prednisone—systemic scleroderma	0.000119	0.000354	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000118	0.000353	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—EDN1—systemic scleroderma	0.000118	0.00111	CbGpPWpGaD
Irbesartan—Anaemia—Methotrexate—systemic scleroderma	0.000118	0.000351	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—HSPG2—systemic scleroderma	0.000117	0.0011	CbGpPWpGaD
Irbesartan—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000348	CcSEcCtD
Irbesartan—Rash—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000345	CcSEcCtD
Irbesartan—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000345	CcSEcCtD
Irbesartan—Headache—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000343	CcSEcCtD
Irbesartan—Malaise—Methotrexate—systemic scleroderma	0.000115	0.000343	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—systemic scleroderma	0.000115	0.000341	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—systemic scleroderma	0.000114	0.00034	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000114	0.000338	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—CSK—systemic scleroderma	0.000113	0.00106	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CCL2—systemic scleroderma	0.000112	0.00105	CbGpPWpGaD
Irbesartan—Paraesthesia—Prednisone—systemic scleroderma	0.000112	0.000333	CcSEcCtD
Irbesartan—Cough—Methotrexate—systemic scleroderma	0.000111	0.000332	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—systemic scleroderma	0.00011	0.000327	CcSEcCtD
Irbesartan—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000325	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—systemic scleroderma	0.000109	0.000324	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—systemic scleroderma	0.000109	0.000324	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—systemic scleroderma	0.000109	0.000324	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—systemic scleroderma	0.000108	0.000323	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000108	0.000321	CcSEcCtD
Irbesartan—Fatigue—Prednisone—systemic scleroderma	0.000107	0.00032	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—systemic scleroderma	0.000107	0.00032	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—EDN1—systemic scleroderma	0.000107	0.00101	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000107	0.001	CbGpPWpGaD
Irbesartan—Constipation—Prednisone—systemic scleroderma	0.000107	0.000317	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000104	0.00031	CcSEcCtD
Irbesartan—Infection—Methotrexate—systemic scleroderma	0.000104	0.000308	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—systemic scleroderma	0.000103	0.000306	CcSEcCtD
Irbesartan—JUN—Immune System—CSK—systemic scleroderma	0.000103	0.000962	CbGpPWpGaD
Irbesartan—Nervous system disorder—Methotrexate—systemic scleroderma	0.000102	0.000304	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000102	0.000304	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000102	0.000303	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—HSPG2—systemic scleroderma	0.000102	0.000955	CbGpPWpGaD
Irbesartan—Skin disorder—Methotrexate—systemic scleroderma	0.000101	0.000301	CcSEcCtD
Irbesartan—JUN—Immune System—IRF5—systemic scleroderma	0.000101	0.000947	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000101	0.0003	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—systemic scleroderma	9.93e-05	0.000296	CcSEcCtD
Irbesartan—Urticaria—Prednisone—systemic scleroderma	9.9e-05	0.000295	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—systemic scleroderma	9.86e-05	0.000293	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—systemic scleroderma	9.86e-05	0.000293	CcSEcCtD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	9.75e-05	0.000915	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RHOB—systemic scleroderma	9.74e-05	0.000914	CbGpPWpGaD
Irbesartan—Hypotension—Methotrexate—systemic scleroderma	9.74e-05	0.00029	CcSEcCtD
Irbesartan—JUN—Immune System—IRF8—systemic scleroderma	9.64e-05	0.000905	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD247—systemic scleroderma	9.64e-05	0.000905	CbGpPWpGaD
Irbesartan—JUN—Immune System—ITGAM—systemic scleroderma	9.64e-05	0.000905	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	9.63e-05	0.000904	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.49e-05	0.000283	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	9.43e-05	0.000885	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMAD7—systemic scleroderma	9.41e-05	0.000883	CbGpPWpGaD
Irbesartan—Paraesthesia—Methotrexate—systemic scleroderma	9.36e-05	0.000278	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—systemic scleroderma	9.29e-05	0.000276	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—EDN1—systemic scleroderma	9.27e-05	0.00087	CbGpPWpGaD
Irbesartan—Somnolence—Methotrexate—systemic scleroderma	9.26e-05	0.000276	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—HSPG2—systemic scleroderma	9.19e-05	0.000862	CbGpPWpGaD
Irbesartan—Hypersensitivity—Prednisone—systemic scleroderma	9.19e-05	0.000273	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—systemic scleroderma	9.17e-05	0.000273	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—systemic scleroderma	9.06e-05	0.00027	CcSEcCtD
Irbesartan—JUN—Immune System—TNFAIP3—systemic scleroderma	9.03e-05	0.000847	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	9e-05	0.000268	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—systemic scleroderma	8.98e-05	0.000267	CcSEcCtD
Irbesartan—Asthenia—Prednisone—systemic scleroderma	8.95e-05	0.000266	CcSEcCtD
Irbesartan—JUN—Immune System—BLK—systemic scleroderma	8.92e-05	0.000837	CbGpPWpGaD
Irbesartan—Pain—Methotrexate—systemic scleroderma	8.91e-05	0.000265	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—CSK—systemic scleroderma	8.87e-05	0.000833	CbGpPWpGaD
Irbesartan—Pruritus—Prednisone—systemic scleroderma	8.82e-05	0.000263	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—systemic scleroderma	8.59e-05	0.000256	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—systemic scleroderma	8.53e-05	0.000254	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.52e-05	0.000254	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—EDN1—systemic scleroderma	8.42e-05	0.00079	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.31e-05	0.00078	CbGpPWpGaD
Irbesartan—Urticaria—Methotrexate—systemic scleroderma	8.28e-05	0.000246	CcSEcCtD
Irbesartan—Dizziness—Prednisone—systemic scleroderma	8.24e-05	0.000245	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—systemic scleroderma	8.24e-05	0.000245	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—systemic scleroderma	8.24e-05	0.000245	CcSEcCtD
Irbesartan—Vomiting—Prednisone—systemic scleroderma	7.93e-05	0.000236	CcSEcCtD
Irbesartan—Rash—Prednisone—systemic scleroderma	7.86e-05	0.000234	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—systemic scleroderma	7.85e-05	0.000234	CcSEcCtD
Irbesartan—Headache—Prednisone—systemic scleroderma	7.81e-05	0.000232	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—CTGF—systemic scleroderma	7.71e-05	0.000724	CbGpPWpGaD
Irbesartan—Hypersensitivity—Methotrexate—systemic scleroderma	7.68e-05	0.000228	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—systemic scleroderma	7.48e-05	0.000223	CcSEcCtD
Irbesartan—Nausea—Prednisone—systemic scleroderma	7.41e-05	0.00022	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—systemic scleroderma	7.37e-05	0.000219	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CCL2—systemic scleroderma	7.33e-05	0.000688	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTLA4—systemic scleroderma	7.31e-05	0.000686	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RHOB—systemic scleroderma	7.28e-05	0.000683	CbGpPWpGaD
Irbesartan—Diarrhoea—Methotrexate—systemic scleroderma	7.13e-05	0.000212	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—systemic scleroderma	6.89e-05	0.000205	CcSEcCtD
Irbesartan—JUN—Signaling Pathways—HSPG2—systemic scleroderma	6.86e-05	0.000644	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.76e-05	0.000635	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CSK—systemic scleroderma	6.63e-05	0.000622	CbGpPWpGaD
Irbesartan—Vomiting—Methotrexate—systemic scleroderma	6.62e-05	0.000197	CcSEcCtD
Irbesartan—Rash—Methotrexate—systemic scleroderma	6.57e-05	0.000196	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—systemic scleroderma	6.56e-05	0.000195	CcSEcCtD
Irbesartan—Headache—Methotrexate—systemic scleroderma	6.53e-05	0.000194	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—EDN1—systemic scleroderma	6.34e-05	0.000595	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.3e-05	0.000591	CbGpPWpGaD
Irbesartan—Nausea—Methotrexate—systemic scleroderma	6.19e-05	0.000184	CcSEcCtD
Irbesartan—JUN—Immune System—HLA-DQB1—systemic scleroderma	6.02e-05	0.000565	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.78e-05	0.000542	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL2—systemic scleroderma	5.76e-05	0.00054	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—HSPG2—systemic scleroderma	5.73e-05	0.000538	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1A—systemic scleroderma	5.71e-05	0.000536	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—systemic scleroderma	5.68e-05	0.000533	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.13e-05	0.000481	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EDN1—systemic scleroderma	4.97e-05	0.000467	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.38e-05	0.000411	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CTGF—systemic scleroderma	4.34e-05	0.000408	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCL2—systemic scleroderma	4.33e-05	0.000407	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NOS3—systemic scleroderma	3.86e-05	0.000362	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EDN1—systemic scleroderma	3.72e-05	0.000349	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HSPG2—systemic scleroderma	3.7e-05	0.000347	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL2—systemic scleroderma	3.4e-05	0.000319	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—NOS3—systemic scleroderma	3.36e-05	0.000315	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—systemic scleroderma	3.1e-05	0.000291	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HSPG2—systemic scleroderma	3.04e-05	0.000285	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOS3—systemic scleroderma	3.03e-05	0.000284	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HSPG2—systemic scleroderma	3.01e-05	0.000283	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—systemic scleroderma	2.98e-05	0.00028	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CTGF—systemic scleroderma	2.8e-05	0.000263	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HSPG2—systemic scleroderma	2.57e-05	0.000242	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—systemic scleroderma	2.55e-05	0.00024	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL2—systemic scleroderma	2.54e-05	0.000238	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—systemic scleroderma	2.43e-05	0.000228	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CTGF—systemic scleroderma	2.3e-05	0.000216	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CTGF—systemic scleroderma	2.28e-05	0.000214	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOS3—systemic scleroderma	2.26e-05	0.000212	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—systemic scleroderma	2e-05	0.000188	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.99e-05	0.000186	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CTGF—systemic scleroderma	1.95e-05	0.000183	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—systemic scleroderma	1.89e-05	0.000177	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—systemic scleroderma	1.82e-05	0.00017	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.51e-05	0.000141	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—systemic scleroderma	1.5e-05	0.000141	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—systemic scleroderma	1.22e-05	0.000115	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—systemic scleroderma	1e-05	9.41e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—systemic scleroderma	9.94e-06	9.33e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—systemic scleroderma	8.49e-06	7.97e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—systemic scleroderma	6.55e-06	6.15e-05	CbGpPWpGaD
